Losartan Potassium Tablet, Film Coated
Product Images NDC 70518-2316

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 70518-2316). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Losartan Potassium 50mg 70518 2316 01

Losartan Potassium 50 mg film-coated tablets in a package containing 30 tablets. The label indicates it is for oral use and is repackaged by RemedyRepack Inc. The original manufacturer is Aurobindo Pharma Ltd., India. The label includes an NDC number 70518-2316-01, storage temperature instructions, a barcode, and a QR code.*

FDA Label Image

Figure1 (Losartan Fig1)

A line graph comparing the percentage of patients with a primary endpoint over study months for Losartan Potassium versus Atenolol. The x-axis shows study duration in months up to 66, and the y-axis indicates the percentage of patients reaching the endpoint, ranging from 0 to 16%. The graph shows a lower percentage for Losartan Potassium compared to Atenolol, with an adjusted risk reduction of 13% (p=0.021).*

FDA Label Image

Figure2 (Losartan Fig2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over study months between Atenolol and Losartan Potassium. The graph shows risk reduction data with Atenolol represented by a dotted line and Losartan Potassium by a solid line. Adjusted risk reduction is noted as 25% with a p-value of 0.001.*

FDA Label Image

Figure 3 (Losartan Fig3)

Figure 3 presents a forest plot comparing primary endpoint events between Losartan Potassium and Atenolol across demographic subgroups. It shows event rates (%) for primary composite and stroke (fatal/non-fatal) outcomes along with hazard ratios and 95% confidence intervals for age, gender, race, ischemic stroke history, diabetes, and cardiovascular disease history.*

FDA Label Image

Figure-4 (Losartan Fig4)

A Kaplan-Meier curve chart showing the percentage of patients with an event over 48 months. The chart compares Losartan Potassium (solid line) versus placebo (dashed line), indicating a risk reduction of 16.1% with Losartan Potassium and a p-value of 0.022.*

FDA Label Image

Chemical Structure (Losartan Str)

Chemical structure of Losartan Potassium depicting its molecular framework including rings, bonds, and key substituents, representing the active ingredient in the Losartan Potassium 50 mg film-coated tablet by RemedyRepack Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.